10 min after jab I noticed a strange taste in my mouth; my throat felt funny; my throat felt funny like it was swelling; dysphagia; felt SOB; elevated BP; Hoarse voice; Abdominal pain; Diarrhea; Nausea; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP and Other HCP). The reporter is the patient.  A 51 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 24Aug2021 16:45 (Lot number: Fe3182) at the age of 51 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Eggs" (unspecified if ongoing), notes: Patient was taking Antihistamine for previous allergic reaction.; "shellfish" (unspecified if ongoing), notes: Patient was taking Antihistamine for previous allergic reaction.; "Antihistamine" (unspecified if ongoing), notes: Patient was taking Antihistamine for previous allergic reaction. The patient took concomitant medications. Past drug history included: Acetaminophen, reaction(s): "Allergy", notes: Patient was taking Antihistamine for previous allergic reaction. The following information was reported: DYSGEUSIA (non-serious) with onset 24Aug2021 17:00, outcome "unknown", described as "10 min after jab I noticed a strange taste in my mouth"; OROPHARYNGEAL DISCOMFORT (non-serious) with onset 24Aug2021 17:00, outcome "unknown", described as "my throat felt funny"; PHARYNGEAL SWELLING (non-serious) with onset 24Aug2021 17:00, outcome "recovering", described as "my throat felt funny like it was swelling"; DYSPHAGIA (non-serious) with onset 2021, outcome "unknown", described as "dysphagia"; DYSPNOEA (non-serious) with onset 2021, outcome "unknown", described as "felt SOB"; BLOOD PRESSURE INCREASED (non-serious) with onset 2021, outcome "unknown", described as "elevated BP"; DYSPHONIA (non-serious) with onset 2021, outcome "unknown", described as "Hoarse voice"; ABDOMINAL PAIN (non-serious) with onset 2021, outcome "unknown", described as "Abdominal pain"; DIARRHOEA (non-serious) with onset 2021, outcome "unknown", described as "Diarrhea"; NAUSEA (non-serious) with onset 2021, outcome "unknown", described as "Nausea". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of dysgeusia, oropharyngeal discomfort, dysphagia, dyspnoea, dysphonia, abdominal pain, diarrhoea, nausea. Therapeutic measures were taken as a result of pharyngeal swelling, blood pressure increased. Additional information: Patient was 51-years-old. Patient was not pregnant at the time of vaccination. Facility vaccine type was reported as Pharmacy or Drug store. Patient did not receive any other vaccine in four weeks. Patient had a history of previous allergies  to specific products included medication, foods (acetaminophen, eggs, shellfish). Patient was taking Antihistamine for previous allergic reaction. It was unknown if patient had previous allergic reaction with hives. Other medications in 2 weeks included BP medicines. On 24Aug2021 at 17:00 15 minutes (also reported as 10 minutes) after jab patient noticed a strange taste in her mouth  and her throat felt funny  like it was swelling. Still felt funny 4 hours later. Patient did not receive any treatment for the adverse events. Patient did not have COVID-19, prior to vaccination and was not test for COVID-19 post vaccination. Patient known allergies included allergy to eggs. Patient provided information to you regarding the reported adverse events with the use of the product and reporter considered that the Pfizer product had a causal effect to the adverse event. Patient received second dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Lot number- FF8839) via an unspecified route of administration on 21Sep2021 as dose 2, single for COVID-19 immunization. Patient did require medical intervention other (anti-hypertensive medication) used for elevated BP and throat felt funny. The patient was not seen in the emergency department. Patient was not hospitalized or was not admitted to an intensive care unit for the adverse events. The adverse events did not result in multi organ involvement. Patient had respiratory system involvement (feet airway constriction). Upper airway swelling included Dysphagia. Patient did not have bilateral wheeze, stridor, respiratory distress, tachypnoea, increased use of accessory respiratory muscles, recession, cyanosis, grunting, dry cough, sneezing, rhinorrhea Shock, tachycardia, capillary refill time was not more than 3 minutes, had no reduced central pulse volume or decreased level of consciousness or loss of consciousness. Patient did not have  dermatological/mucosal, generalized urticarial, Generalized erythema, angioedema, generalized pruritus with skin rash, generalized pruritus without skin rash, generalized prickle sensation, localized injection site urticarial, red and itchy eyes. Patient had hoarse voice, difficulty breathing (felt SOB), sensation of throat closure (felt throat funny like) and cardiovascular symptoms which included elevated BP. Patient did not measure hypotension. Patient had gastrointestinal symptoms which included diarrhea, abdominal pain, nausea , but had no vomiting on an unspecified date in 2021. The adverse events elevated BP and throat felt funny resulted in the initiation of new medication or other treatment or procedure (additional hypertensive medications required). Patient was taking medications prior to the event being reported. Patient did not receive any recent vaccines for any other conditions prior to the event being reported. Patient did not receive any recent vaccines for SARS-CoV-2 other than Pfizer-BioNTech COVID-19 Vaccine prior to the event being reported. Patient did not received any other vaccines around the time of Pfizer-BioNTech COVID-19 Vaccine vaccination.  Patients outcome following the potential anaphylactic reaction was recovering for the events throat was swelling while for the other events it was unknown.  No follow-up attempts are possible. No further information is expected.  Follow-Up (01Oct2021): Follow-up attempts are completed. No further information is expected.